Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients
Stanniocalcin-1 (STC1) is a secreted glycoprotein hormone and highly expressed in various types of human malignancies. Although evidence points to the role of STC1 in human cancers, the clinical significance of STC1 expression in glioma has not been established. Here, we investigated the relationshi...
Gespeichert in:
| Veröffentlicht in: | Tumor biology 2015-08, Vol.36 (8), p.6333-6339 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6339 |
|---|---|
| container_issue | 8 |
| container_start_page | 6333 |
| container_title | Tumor biology |
| container_volume | 36 |
| creator | Su, Jingyuan Guo, Bingyu Zhang, Tingting Wang, Kanwen Li, Xiaoming Liang, Guobiao |
| description | Stanniocalcin-1 (STC1) is a secreted glycoprotein hormone and highly expressed in various types of human malignancies. Although evidence points to the role of STC1 in human cancers, the clinical significance of STC1 expression in glioma has not been established. Here, we investigated the relationship between STC1 expression and clinicopathological significance in glioma. In our study, we selected 60 cases of different grades glioma tissues to detect the expression of STC1. Data showed that the mRNA and protein levels of STC1 in high-grade glioma tissues were significantly higher than that in low-grade tissues. The results of double immunofluorescent staining disclosed STC1 distribution in vascular endothelial cells and the cytoplasm in high-grade glioma, but almost distributed only in vascular endothelial cells in low-grade glioma. By immunohistochemistry, we got the same results and the expression of STC1 has significant difference in high-grade gliomas and low-grade gliomas. Furthermore, the results of Kaplan–Meier analysis indicated that cases with high STC1expression had significantly worse overall survival than those with low level of STC1. These results suggested that STC1 may be a valuable biomarker in diagnosing malignant degree of glioma and evaluating prognostic following surgery. Next, we would study the pathophysiological mechanism of STC1 in glioma. |
| doi_str_mv | 10.1007/s13277-015-3319-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1859475727</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3785385031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-fdebb052c95e5f9dda52add5302fd03907cdaf9788ae484e0a68044dba3700ae3</originalsourceid><addsrcrecordid>eNqFkctuFDEQRa2IiDzgA9hEltiwiEP5NW4vURQCUqQsgLVxt6sHhx57Yvcoyt_Hk0kQQkJZ2dY9t6pcl5B3HM44gPlYuRTGMOCaScktgz1yyJWQDGQHr9odODAlOnlAjmq9gQZau3hNDoQ2ndTCHpKf32afUsyDn4aYGD-lnia8o33MK19-Y6F5pMtp-6LrkpcFa405ndJYqa81D9HPGOhdnH896inXpjTP2s8R01zfkP3RTxXfPp3H5Mfni-_nX9jV9eXX809XbFBGz2wM2PegxWA16tGG4LXwIWgJYgwgLZgh-NGarvOoOoXgFx0oFXovDYBHeUw-7Oq2KW43WGe3inXAafIJ86Y63mnbOhlhXkYNLNqCFlo19P0_6E3elNQ-8kgBN4rzRvEdNZRca8HRrUts67t3HNw2KbdLyrUA3DYpB81z8lR5068w_HE8R9MAsQNqk9ISy1-t_1v1Acz0nhY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1706017411</pqid></control><display><type>article</type><title>Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Su, Jingyuan ; Guo, Bingyu ; Zhang, Tingting ; Wang, Kanwen ; Li, Xiaoming ; Liang, Guobiao</creator><creatorcontrib>Su, Jingyuan ; Guo, Bingyu ; Zhang, Tingting ; Wang, Kanwen ; Li, Xiaoming ; Liang, Guobiao</creatorcontrib><description>Stanniocalcin-1 (STC1) is a secreted glycoprotein hormone and highly expressed in various types of human malignancies. Although evidence points to the role of STC1 in human cancers, the clinical significance of STC1 expression in glioma has not been established. Here, we investigated the relationship between STC1 expression and clinicopathological significance in glioma. In our study, we selected 60 cases of different grades glioma tissues to detect the expression of STC1. Data showed that the mRNA and protein levels of STC1 in high-grade glioma tissues were significantly higher than that in low-grade tissues. The results of double immunofluorescent staining disclosed STC1 distribution in vascular endothelial cells and the cytoplasm in high-grade glioma, but almost distributed only in vascular endothelial cells in low-grade glioma. By immunohistochemistry, we got the same results and the expression of STC1 has significant difference in high-grade gliomas and low-grade gliomas. Furthermore, the results of Kaplan–Meier analysis indicated that cases with high STC1expression had significantly worse overall survival than those with low level of STC1. These results suggested that STC1 may be a valuable biomarker in diagnosing malignant degree of glioma and evaluating prognostic following surgery. Next, we would study the pathophysiological mechanism of STC1 in glioma.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-015-3319-0</identifier><identifier>PMID: 25783529</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adolescent ; Adult ; Aged ; Biomarkers ; Biomarkers, Tumor - biosynthesis ; Biomarkers, Tumor - genetics ; Biomedical and Life Sciences ; Biomedicine ; Brain cancer ; Brain Neoplasms - genetics ; Brain Neoplasms - pathology ; Cancer Research ; Child ; Disease Progression ; Female ; Glioma - genetics ; Glioma - pathology ; Glycoproteins ; Glycoproteins - biosynthesis ; Glycoproteins - genetics ; Humans ; Kaplan-Meier Estimate ; Male ; Medical prognosis ; Middle Aged ; Neoplasm Grading ; Prognosis ; Protein expression ; Research Article ; RNA, Messenger - biosynthesis</subject><ispartof>Tumor biology, 2015-08, Vol.36 (8), p.6333-6339</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-fdebb052c95e5f9dda52add5302fd03907cdaf9788ae484e0a68044dba3700ae3</citedby><cites>FETCH-LOGICAL-c475t-fdebb052c95e5f9dda52add5302fd03907cdaf9788ae484e0a68044dba3700ae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13277-015-3319-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13277-015-3319-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25783529$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Su, Jingyuan</creatorcontrib><creatorcontrib>Guo, Bingyu</creatorcontrib><creatorcontrib>Zhang, Tingting</creatorcontrib><creatorcontrib>Wang, Kanwen</creatorcontrib><creatorcontrib>Li, Xiaoming</creatorcontrib><creatorcontrib>Liang, Guobiao</creatorcontrib><title>Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients</title><title>Tumor biology</title><addtitle>Tumor Biol</addtitle><addtitle>Tumour Biol</addtitle><description>Stanniocalcin-1 (STC1) is a secreted glycoprotein hormone and highly expressed in various types of human malignancies. Although evidence points to the role of STC1 in human cancers, the clinical significance of STC1 expression in glioma has not been established. Here, we investigated the relationship between STC1 expression and clinicopathological significance in glioma. In our study, we selected 60 cases of different grades glioma tissues to detect the expression of STC1. Data showed that the mRNA and protein levels of STC1 in high-grade glioma tissues were significantly higher than that in low-grade tissues. The results of double immunofluorescent staining disclosed STC1 distribution in vascular endothelial cells and the cytoplasm in high-grade glioma, but almost distributed only in vascular endothelial cells in low-grade glioma. By immunohistochemistry, we got the same results and the expression of STC1 has significant difference in high-grade gliomas and low-grade gliomas. Furthermore, the results of Kaplan–Meier analysis indicated that cases with high STC1expression had significantly worse overall survival than those with low level of STC1. These results suggested that STC1 may be a valuable biomarker in diagnosing malignant degree of glioma and evaluating prognostic following surgery. Next, we would study the pathophysiological mechanism of STC1 in glioma.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - biosynthesis</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain cancer</subject><subject>Brain Neoplasms - genetics</subject><subject>Brain Neoplasms - pathology</subject><subject>Cancer Research</subject><subject>Child</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Glioma - genetics</subject><subject>Glioma - pathology</subject><subject>Glycoproteins</subject><subject>Glycoproteins - biosynthesis</subject><subject>Glycoproteins - genetics</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Prognosis</subject><subject>Protein expression</subject><subject>Research Article</subject><subject>RNA, Messenger - biosynthesis</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkctuFDEQRa2IiDzgA9hEltiwiEP5NW4vURQCUqQsgLVxt6sHhx57Yvcoyt_Hk0kQQkJZ2dY9t6pcl5B3HM44gPlYuRTGMOCaScktgz1yyJWQDGQHr9odODAlOnlAjmq9gQZau3hNDoQ2ndTCHpKf32afUsyDn4aYGD-lnia8o33MK19-Y6F5pMtp-6LrkpcFa405ndJYqa81D9HPGOhdnH896inXpjTP2s8R01zfkP3RTxXfPp3H5Mfni-_nX9jV9eXX809XbFBGz2wM2PegxWA16tGG4LXwIWgJYgwgLZgh-NGarvOoOoXgFx0oFXovDYBHeUw-7Oq2KW43WGe3inXAafIJ86Y63mnbOhlhXkYNLNqCFlo19P0_6E3elNQ-8kgBN4rzRvEdNZRca8HRrUts67t3HNw2KbdLyrUA3DYpB81z8lR5068w_HE8R9MAsQNqk9ISy1-t_1v1Acz0nhY</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Su, Jingyuan</creator><creator>Guo, Bingyu</creator><creator>Zhang, Tingting</creator><creator>Wang, Kanwen</creator><creator>Li, Xiaoming</creator><creator>Liang, Guobiao</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20150801</creationdate><title>Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients</title><author>Su, Jingyuan ; Guo, Bingyu ; Zhang, Tingting ; Wang, Kanwen ; Li, Xiaoming ; Liang, Guobiao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-fdebb052c95e5f9dda52add5302fd03907cdaf9788ae484e0a68044dba3700ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - biosynthesis</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain cancer</topic><topic>Brain Neoplasms - genetics</topic><topic>Brain Neoplasms - pathology</topic><topic>Cancer Research</topic><topic>Child</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Glioma - genetics</topic><topic>Glioma - pathology</topic><topic>Glycoproteins</topic><topic>Glycoproteins - biosynthesis</topic><topic>Glycoproteins - genetics</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Prognosis</topic><topic>Protein expression</topic><topic>Research Article</topic><topic>RNA, Messenger - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Su, Jingyuan</creatorcontrib><creatorcontrib>Guo, Bingyu</creatorcontrib><creatorcontrib>Zhang, Tingting</creatorcontrib><creatorcontrib>Wang, Kanwen</creatorcontrib><creatorcontrib>Li, Xiaoming</creatorcontrib><creatorcontrib>Liang, Guobiao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Su, Jingyuan</au><au>Guo, Bingyu</au><au>Zhang, Tingting</au><au>Wang, Kanwen</au><au>Li, Xiaoming</au><au>Liang, Guobiao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients</atitle><jtitle>Tumor biology</jtitle><stitle>Tumor Biol</stitle><addtitle>Tumour Biol</addtitle><date>2015-08-01</date><risdate>2015</risdate><volume>36</volume><issue>8</issue><spage>6333</spage><epage>6339</epage><pages>6333-6339</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>Stanniocalcin-1 (STC1) is a secreted glycoprotein hormone and highly expressed in various types of human malignancies. Although evidence points to the role of STC1 in human cancers, the clinical significance of STC1 expression in glioma has not been established. Here, we investigated the relationship between STC1 expression and clinicopathological significance in glioma. In our study, we selected 60 cases of different grades glioma tissues to detect the expression of STC1. Data showed that the mRNA and protein levels of STC1 in high-grade glioma tissues were significantly higher than that in low-grade tissues. The results of double immunofluorescent staining disclosed STC1 distribution in vascular endothelial cells and the cytoplasm in high-grade glioma, but almost distributed only in vascular endothelial cells in low-grade glioma. By immunohistochemistry, we got the same results and the expression of STC1 has significant difference in high-grade gliomas and low-grade gliomas. Furthermore, the results of Kaplan–Meier analysis indicated that cases with high STC1expression had significantly worse overall survival than those with low level of STC1. These results suggested that STC1 may be a valuable biomarker in diagnosing malignant degree of glioma and evaluating prognostic following surgery. Next, we would study the pathophysiological mechanism of STC1 in glioma.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>25783529</pmid><doi>10.1007/s13277-015-3319-0</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1010-4283 |
| ispartof | Tumor biology, 2015-08, Vol.36 (8), p.6333-6339 |
| issn | 1010-4283 1423-0380 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1859475727 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Adult Aged Biomarkers Biomarkers, Tumor - biosynthesis Biomarkers, Tumor - genetics Biomedical and Life Sciences Biomedicine Brain cancer Brain Neoplasms - genetics Brain Neoplasms - pathology Cancer Research Child Disease Progression Female Glioma - genetics Glioma - pathology Glycoproteins Glycoproteins - biosynthesis Glycoproteins - genetics Humans Kaplan-Meier Estimate Male Medical prognosis Middle Aged Neoplasm Grading Prognosis Protein expression Research Article RNA, Messenger - biosynthesis |
| title | Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T19%3A50%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stanniocalcin-1,%20a%20new%20biomarker%20of%20glioma%20progression,%20is%20associated%20with%20prognosis%20of%20patients&rft.jtitle=Tumor%20biology&rft.au=Su,%20Jingyuan&rft.date=2015-08-01&rft.volume=36&rft.issue=8&rft.spage=6333&rft.epage=6339&rft.pages=6333-6339&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-015-3319-0&rft_dat=%3Cproquest_cross%3E3785385031%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1706017411&rft_id=info:pmid/25783529&rfr_iscdi=true |